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Abstract 20 
Human IFITMs were identified as restriction factors of influenza A virus (IAV). Given the important 21 
role of pigs in the zoonotic cycle of IAV we cloned swine IFITMs (swIFITM) and found two 22 
IFITM1-like proteins, one homologue of IFITM2 and one of IFITM3. We show that swIFITM2 and 23 
swIFITM3 localize to endosomes and display potent antiviral activity. Knockdown of swIFITMs 24 
strongly reduced virus inhibition by interferon establishing the swIFITMs as potent restriction 25 
factors in porcine cells.  26 
Main text 27 
The interferon-inducible transmembrane proteins (IFITMs) were identified as potent inhibitors of 28 
different viruses, including influenza A virus (IAV), West Nile Virus, SARS coronavirus and others 29 
(1-5). In particular, human and mouse IFITM3 have been studied regarding their antiviral potential 30 
but also the mechanism of viral restriction. Ifitm3 knockout mice showed accelerated disease 31 
progression and higher morbidity and mortality upon IAV infection (6). Moreover, it was found that 32 
humans with a single nucleotide polymorphism in the ifitm3 gene have a significantly higher risk 33 
for a severe course of IAV infection (6, 7). The antiviral mechanism of the IFITMs is not yet fully 34 
understood but it has become clear that viral fusion is targeted by these proteins (8-11). While we 35 
have a good understanding of the antiviral potential of human and mouse IFITMs, much less is 36 
known about the activity of IFITMs in other species. Given the important role of pigs in the 37 
zoonotic cycle of IAV we aimed to elucidate the antiviral potential of swine IFITM (swIFITM) 38 
proteins. 39 
We cloned swIFITMs from cDNA obtained from interferon (IFN)-stimulated pig cells according to 40 
sequences deposited in the NCBI database. We were able to amplify the porcine homologues of 41 
human IFITM1, IFITM2 and IFITM3. For IFITM1, two porcine homologues that differ in their N- 42 
and C-termini, named swIFITM1a and 1b, were found. Swine IFITM5 could not be amplified out 43 
of cDNA and was thus synthesized. The amino acid alignment of the IFITM proteins from 44 
humans, pigs and chickens shows that the IFITMs display certain features that are conserved 45 
across all three species, such as the two transmembrane domains, the palmitoylation sites at 46 
positions 73 and 74 or the ubiquitination sites at positions 85, 90 and 106 (Fig.1A) (12-14). 47 
Moreover, swine and human IFITM2 and IFITM3 share an N-terminal extension of about 20 48 
amino acids that contains the endocytosis motif YEML, which the IFITM1 proteins of both species 49 
lack (Fig.1A) (15, 16). This alignment suggests that the swine IFITM proteins could have similar 50 
antiviral properties as their human counterparts. 51 
The induction of human IFITM1-3 upon IFN stimulation or virus infection is well-established (1, 52 
17). While Miller et al. showed that in pigs swIFITMs are induced in tracheobronchial lymph 53 
nodes upon infection (18), a direct induction of swIFITMs upon IFN treatment has not been 54 
established to date. We thus tested the inducibility of swIFITMs upon IFN stimulation or IAV 55 
infection in porcine cell lines. We stimulated porcine NpTr, PK-15 or NSK cells with universal IFN 56 
(1000 U/ml) for 24h or infected with A/WSN/33 (WSN) (MOI 0.01) for 24h or 48h (19). RT-qPCR 57 
with specific primers for the individual swIFITMs (primer sequences available upon request) 58 
revealed a pronounced upregulation of swIFITM1a, swIFITM1b, swIFITM2 and swIFITM3 upon 59 
IFN-stimulation or infection in NSK as well as PK-15 cells (Fig.1B, C). In contrast, swIFITM 60 
transcripts were induced less than 3-fold in NpTr cells (Fig.1D). Moreover, when we treated NpTr 61 
cells with strong inducers of the IFN response, such as IAV lacking NS1, poly(I:C) or a 62 
preparation of Sendaivirus that contains large amounts of defective interfering particles, we 63 
detected only low levels of swIFITM induction (Fig.1E). This was not limited to swIFITMs; also 64 
swine MX1 and swine OAS, both known to be upregulated by IFN, displayed only low levels of 65 
induction. This suggests that the NpTr cells are not able to mount a strong IFN response. Despite 66 
these differences in the induction of the swIFITMs, all three cell lines were permissive for robust 67 
replication of IAV (Fig.1F). Expression of swIFITM5 could not be detected in any of the cell lines 68 
(data not shown). These results suggest that like their human counterparts, swIFITM1-3 69 
constitute a first line of defence against viral infections.  70 
Next, we analyzed the subcellular localization of the swIFITMs. We transiently transfected human 71 
A549, swine NpTr or swine NSK cells with constructs encoding flag-tagged human or swine 72 
IFITMs. IFITM proteins were stained using an antibody against the flag-tag, while late endosomes 73 
were marked using an antibody recognizing lysobisphosphatidic acid (LBPA) (20). Confocal 74 
microscopy revealed that the subcellular localization of porcine IFITMs is similar to their human 75 
homologues, with swIFITM1a and 1b localizing predominantly to the plasma membrane while 76 
swIFITM2 and 3 accumulate in late endosomes. This is illustrated by their co-localization with the 77 
late endosomal marker LBPA in representative images (Fig.2A) and the quantification of co-78 
localization from 8-12 cells per construct and cell line (Fig.2B). Of note, human and swine IFITM2 79 
displayed the highest degree of co-localization with LBPA. The observed localization for the 80 
human IFITMs is in agreement with previous reports for overexpressed but also for endogenous 81 
human IFITMs validating our approach (8). Moreover, the endosomal localization of human and 82 
swine IFITM2 and 3 confirms the importance of the endocytosis motif in the N-terminus for 83 
pronounced localization to endosomes (15, 16). When we analyzed the localization of the 84 
swIFITM proteins during IAV infection we did not detect changes in their intracellular distribution 85 
compared to uninfected cells (Fig.2C).  86 
To evaluate the antiviral potential of swIFITMs we performed an IAV reporter assay in cells 87 
transiently transfected with the different swIFITMs. The reporter plasmid encodes luciferase in 88 
complementary reverse orientation flanked by IAV non-coding regions, preceded by a human or 89 
swine pPolI promoter for use in human or porcine cells, respectively. This assay provides the 90 
advantage that only reporter activity from transfected cells is measured, enabling us to assess 91 
the impact of the different IFITM proteins on IAV in a transient transfection system. The construct 92 
for human cells has been used before (21) and, for porcine cells, we adapted a construct 93 
described previously by introducing three mutations at positions 3, 5 and 8 in the promoter region 94 
(22, 23). After transfection with the reporter plasmid plus the indicated IFITM-encoding plasmid, 95 
we infected with IAV A/WSN/33 at an MOI of 0.1 in HEK293-T and an MOI of 1 in NpTr cells and 96 
measured luciferase production 24h post infection (p.i.). We observed that swIFITMs show a 97 
dose-dependent restriction of IAV in HEK293-T cells, with swIFITM2 and 3 being the most 98 
antivirally active and their activity being comparable to huIFITM3 (Fig.3A). However, it should 99 
also be noted that swIFITM2, swIFITM3 and huIFITM3 were expressed to higher levels than the 100 
other IFITMs, which is in line with the dose-dependency of restriction. We then confirmed the 101 
antiviral activity of swIFITMs in porcine cells, with swIFITM2 showing the most potent restriction 102 
of IAV (Fig.3B). These data from the transient transfection assay suggest that the swIFITM 103 
proteins possess antiviral activity. 104 
In order to corroborate these findings, we generated stable cell lines overexpressing the different 105 
swIFITMs in the background of the porcine NpTr and NSK cells by lentiviral transduction. Cells 106 
were subcloned until more than 99% of cells were positive for expression. To test the antiviral 107 
activity of overexpressed swIFITMs we infected the cell lines with either the human strain 108 
A/HongKong/68 (MOI 1), or the swine isolate A/swine/Zurich/25/06 (MOI 1). At 48h p.i., 109 
supernatants were harvested and viral titers determined by plaque assay. Expression of the 110 
swIFITMs reduced viral titers of IAV in the NpTr cell lines, with swIFITM2 being the most potent 111 
and reducing titers around 1000-fold (Fig.3C, D). It should be noted that we were not able to 112 
generate stable NpTr cell lines expressing high levels of swIFITM3 and 5 (Fig.3E), which could 113 
contribute to the reduced potency of swIFITM3 compared to swIFITM2. In the NSK cell lines, we 114 
also observed potent inhibition of IAV replication upon expression of the different swIFITMs, 115 
except for swIFITM1b (Fig.3F, G). Again, swIFITM2 displayed the most potent antiviral activity. 116 
As in the NpTr cells, we were not able to generate cell lines expressing high levels of swIFITM3 117 
or swIFITM5. These data suggest that high expression levels of these two swIFITM proteins are 118 
not well tolerated in porcine cells. The differences in expression levels make a direct comparison 119 
of the antiviral activity difficult since we observed in the transient transfection assay in 293T that 120 
higher expression levels lead to better inhibition of IAV. However, when comparing swIFITM2 to 121 
swIFTIM1a or 1b, expression levels are similar but swIFITM2 is the most active. Moreover, 122 
swIFITM3 despite being expressed at much lower levels than swIFITM1a or 1b has comparable 123 
activity. We therefore suggest that swIFITM2 and swIFITM3 which localize predominantly to late 124 
endosomes display the strongest antiviral potential. 125 
Since the assays described above were performed with overexpressed swIFITMs, we next 126 
assessed whether endogenous swIFITMs also reduce viral replication. To this aim, porcine NSK 127 
cells were transfected with two different siRNAs targeting swIFITMs (siIFITM #1, siIFITM #2), a 128 
positive control siRNA against the viral nucleoprotein NP or a negative control non-targeting 129 
siRNA. At 36h post transfection, cells were either mock-treated or treated with universal type I 130 
IFN (1000 U/ml). At 12h post treatment, cells were infected with IAV A/WSN/33 (MOI 0.0001), 131 
supernatants were harvested at 24h p.i. and virus titers were determined by plaque assay. In the 132 
absence of IFN, knockdown of swIFITM had no effect on virus titers (Fig.4A grey bars). However, 133 
in IFN-treated cells, viral titers were increased by 10-fold when swIFITMs were downregulated 134 
(Fig.4A black bars). To confirm that knockdown by siRNA was successful we measured mRNA 135 
levels for the different swIFITMs and swMX1 in parallel samples and found that both siRNAs 136 
designed to target all IFN-induced swIFITMs potently downregulated their expression, whereas 137 
swMX1 as a control IFN-stimulated gene was not affected (Fig.4B, C). Knockdown of swIFITMs 138 
by the two different siRNAs was further confirmed at the level of protein. Since detection of 139 
endogenous porcine swIFITM proteins was unsuccessful using available antibodies for human 140 
IFITMs we tested the siRNAs in the NSK cell lines overexpressing swIFITMs and confirmed 141 
knockdown (Fig.4D). Downregulation of viral NP levels by the NP-specific siRNA was also 142 
confirmed by western blot (Fig.4E). These data show that swIFITMs constitute an important part 143 
of the IFN response against IAV in porcine cells and confirm our results obtained with 144 
overexpression of swIFITMs.  145 
In summary, we show that swIFITM1-3 are upregulated by type I IFN and IAV infection in porcine 146 
PK-15 and NSK cells. While swIFITM1a and 1b displayed prominent plasma-membrane 147 
localization, swIFITM 2 and 3 were found to co-localize with a marker for late endosomes. Over-148 
expression of swIFITMs resulted in reduced influenza virus reporter activity and reduced viral 149 
titers. Although different expression levels of the swIFITMs make a direct comparison of the 150 
antiviral potencies difficult the data suggest that swIFITM2 and swIFITM3 display the strongest 151 
antiviral activity. Importantly, we also show that endogenous swIFITMs constitute a large part of 152 
the antiviral activity of IFN in porcine cells. In future studies, it will be interesting to characterize 153 
the IFITMs from different swine breeds for their antiviral potential and thereby help to select pig 154 
breeds with increased resistance to IAV infections.  155 
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  244 
Figure legends 245 
Figure 1. Amino acid alignment of human, swine and chicken IFITM proteins and induction 246 
of swine IFITMs upon IFN stimulation or virus infection. (A) Amino acid alignment of human, 247 
swine and chicken IFITM1, IFITM2, IFITM3 and IFITM5. Functional motifs and domains are 248 
highlighted with colored boxes. Abbreviations: hu human, sw swine, ch chicken, TM 249 
transmembrane domain (B-D) Induction of swIFITM expression by IFN or IAV infection. NSK (B), 250 
PK15 (C) or NpTr (D) porcine cells were infected with A/WSN/33 at an MOI of 0.01 or treated with 251 
universal IFN (1000 U/ml) for 24h. At the indicated times post treatment, total mRNA was 252 
extracted and used to perform RT-qPCR using specific oligos for the different swIFITMs or 253 
swMX1 as positive control. Fold-changes were calculated according to the Pfaffl method using 254 
swGAPDH mRNA as reference. A representative experiment from two biological replicates, each 255 
performed in triplicate, is shown with error bars representing the 95% confidence interval. 256 
Statistical significance between IFN-treated or IAV-infected cells and control untreated cells was 257 
assessed by an unpaired two-tailed Student’s t test (*, P<0.05). (E) NpTr cells were transfected 258 
with poly(I:C) or infected with A/PR/8/34ΔNS1 (ΔNS1) or Sendaivirus (SeV) for 24h. Total mRNA 259 
was extracted and used to perform RT-qPCR using specific oligos. Fold-changes were calculated 260 
according to the Pfaffl method using swGAPDH mRNA as reference. A representative experiment 261 
is shown with error bars representing the 95% confidence interval. Statistical significance 262 
between poly(I:C)-treated or infected cells and control untreated cells was assessed by an 263 
unpaired two-tailed Student’s t test (*, P<0.05). (F) IAV replication in porcine cell lines. NSK, PK-264 
15 and NpTr cells were infected with A/WSN/33 as described in B-D and viral titers in the 265 
supernatant at 24/48h p.i. were determined by plaque assay. The dashed line indicates the limit 266 
of detection. 267 
Figure 2. Localization of human and swine IFITM proteins in human and porcine cells. (A) 268 
Representative confocal images of human A549 (a-g), porcine NpTr cells (h-k) or porcine NSK 269 
cells (l-o) transfected with flag-tagged human or porcine IFITM-encoding constructs are shown. 270 
IFITMs were stained using an antibody against the flag-epitope (red), late endosomes using an 271 
antibody against the late endosomal marker LBPA (green) and cell nuclei were marked using 272 
DAPI (blue). Cells were imaged using a 63x objective and a magnification of 3x (scale bar = 10 273 
μm) (B) Co-localization of IFITM proteins with the late endosome marker LBPA was quantified. 274 
Horizontal bars represent the mean of the Pearson’s correlation coefficient (Rr) calculated for 8-275 
12 cells using ImageJ, with error bars marking the 95% confidence interval. Statistical 276 
significance of increased co-localization for the indicated IFITM construct compared to huIFITM1 277 
or swIFITM1a, respectively, was assessed by an unpaired two-tailed Student’s t test (*, P<0.05; 278 
**, P<0.01; ***, P<0.001; ****, P<0.0001). (C) Representative confocal images of NSK cells 279 
transfected with flag-tagged porcine IFITM-encoding constructs and infected with A/WSN/33 at 280 
an MOI of 5 are shown. IFITMs were stained using an antibody against the flag-epitope (red), 281 
infection was controlled using an antibody against IAV NP (green) and cell nuclei were marked 282 
using DAPI (blue). Cells were imaged using a 63x objective and a magnification of 3x (scale bar 283 
= 10 μm). 284 
Figure 3. Expression of swIFITMs potently inhibits IAV. (A-B) Transient transfection 285 
assays. HEK293-T (A) and NpTr (B) cells were transfected with an IAV-dependent firefly 286 
luciferase reporter construct and increasing amounts of plasmids encoding flag-tagged swine 287 
IFITMs. At 24h post transfection, cells were infected with A/WSN/33 at an MOI of 0.1 (A) or 1 (B). 288 
At 24h p.i., cells were lyzed and firefly luciferase activity measured. Data were normalized to 289 
luciferase activity in cells transfected with an inactive Mx1 mutant (neg con), while murine Mx1 290 
and human IFITM3 served as positive controls (pos con). Mean values from three biological 291 
replicates, each performed in triplicate, are shown with error bars representing standard 292 
deviation. Statistical significance between cells transfected with swIFITMs and cells expressing 293 
the negative control was assessed by an unpaired two-tailed Student’s t test (*, P<0.05; **, 294 
P<0.01; ***, P<0.001; ****, P<0.0001). Expression levels of swine IFITM proteins were confirmed 295 
by western blot, quantified using Multi Gauge software and expression levels in relation to human 296 
IFITM3 expression are given below the western blots. (C-H) Stable cell lines expressing 297 
swIFITMs. NpTr (C, D) or NSK (F, G) cells stably overexpressing flag-tagged swIFITM proteins 298 
were infected with A/HongKong/68 (MOI 1) (C, F) or A/swine/Zurich/25/06 (MOI 1) (D, G). At 48h 299 
p.i., supernatants were harvested and virus titers determined via plaque assay on MDCK cells. 300 
Mean values from three replicates are shown with error bars representing standard deviation. 301 
Statistical significance between titers from cells expressing swIFITM proteins and cells 302 
transduced with the empty vector (con) was assessed by an unpaired two-tailed Student’s t test 303 
(*, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001). The dashed lines indicate the limit of 304 
detection. Expression levels of swIFITMs were confirmed by western blot, quantified by Multi 305 
Gauge software and expression levels relative to the strongest band are given below the western 306 
blots (E, H).  307 
Figure 4. Endogenous swIFITMs contribute to the antiviral activity of IFN in porcine cells. 308 
(A) NSK cells were transfected with two siRNAs targeting swIFITMs (#1 and #2) or the viral 309 
nucleoprotein (NP) or a non-targeting control siRNA. At 36h post transfection, cells were either 310 
left untreated or treated with universal type I IFN (1000 U/ml). At 12h post treatment, cells were 311 
infected with A/WSN/33 (MOI 0.0001) and supernatants were harvested at 24h p.i. Viral titers 312 
were determined by plaque assay. Mean values with standard deviation from three replicates are 313 
shown. The dashed line indicates the limit of detection. (B, C) A parallel set of samples was 314 
siRNA-transfected and mock or interferon-treated as above. At 48h post transfection, cells were 315 
harvested and mRNA levels of the different swIFITMs and swMX1 were determined by RT-qPCR. 316 
Fold-changes were calculated according to the Pfaffl method using swGAPDH mRNA as 317 
reference. Mean values with the 95% confidence interval from three replicates are shown. 318 
Statistical significance between NP- or swIFITM-silenced cells and cells transfected with the non-319 
targeting siRNA was assessed by an unpaired two-tailed Student’s t test (*, P<0.05). (D) Stable 320 
NSK cells expressing swIFITMs were transfected with either an siRNA targeting swIFITMs or a 321 
non-targeting control siRNA (con). At 48h post transfection cells were lyzed and the amount of 322 
flag-tagged swIFITMs assessed by western blot. Results for two different swIFITM-specific 323 
siRNAs (#1 and #2) are shown. (E) NSK cells were transfected with either an siRNA targeting 324 
IAV NP or a non-targeting control siRNA (con) . At 36h post transfection cells were treated with 325 
universal type I IFN (1000 U/ml) and 12h post treatment cells were infected with A/WSN/33 (MOI 326 
0.0001) as in 4A. At 24h p.i. cells were lyzed and NP levels assessed by western blot. 327 




